Oxford University starts the first human trial of a COVID-19 vaccine
- Author: Ismael Montgomery Apr 25, 2020,
Apr 25, 2020, 0:20
In a press release, the German regulatory authority Paul-Ehrlich-Institut said that a biotechnology company's vaccine program was authorized for human trials after careful consideration of the potential risks and benefits.
In a first stage, in this trial will participate 200 healthy people between the ages of 18 and 55 years of age and will be vaccinated with "one of several variants of the vaccine are slightly modified".
Now, according to a report, Germany has authorised their first clinical trial of a vaccine - the fourth lobally to enter the clinical trial phase. "At the same time, it's important to remember that it will take months before a vaccine will be fully tested and can actually be available". We hope that we have succeeded by giving you the full details and information. "Now that the work in Germany can commence, we are looking forward to and actively preparing for the potential start of this unique and robust clinical study program in the USA soon", Albert Bourla, Pfizer Chairman and CEO, said.
The provision of authorised safe and efficacious COVID-19 vaccines is a central aim in combating the rampant new SARS Coronavirus-2 (SARS-CoV-2).
Turkish professor Ugur Sahin's BioNTech company and pharma giant Pfizer are jointly developing vaccine candidates, as part of a global development program.
Also on Wednesday, BioNTech and US pharmaceutical company Pfizer announced that they would jointly develop the BNT162 vaccine as "part of a global development program", BioNTech said.
Canada police arrest suspected gunman, say there are 'several victims'
According to a series of tweets from Nova Scotia RCMP on Sunday morning, the suspect was Gabriel Wortman, a 51-year-old man. Mr Taggart said he did not know Mr Wortman well, but spoke to him a few times when he telephoned about municipal issues.
Health Secretary Matt Hancock has praised both teams and said the United Kingdom will "throw everything we've got" at developing a vaccine.
Phase 3 and 4 trials track the effectiveness of the vaccine in preventing infection in people exposed to the pathogen.
Last month a newspaper report alleged that the USA had attempted to buy exclusive rights to vaccine research being carried out by CureVac, another German firm.
Although at least 120 projects around the world are working towards a vaccine, just 5 clinical trials on humans have so far been approved.